These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29501421)

  • 1. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
    Li S; Zhao J; Wang Q
    J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.
    Zaemes J; Hall RD; Gentzler RD
    J Thorac Oncol; 2018 Aug; 13(8):e136-e137. PubMed ID: 30049373
    [No Abstract]   [Full Text] [Related]  

  • 3. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 4. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
    Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
    Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
    [No Abstract]   [Full Text] [Related]  

  • 5. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
    Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
    [No Abstract]   [Full Text] [Related]  

  • 6. A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Liang P; Qi L; Guo T; You X; Cui C
    Lung Cancer; 2021 Feb; 152():193-195. PubMed ID: 33388164
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
    Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
    J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
    [No Abstract]   [Full Text] [Related]  

  • 8. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
    Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
    Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
    Fang W; Huang Y; Gan J; Shao YW; Zhang L
    J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
    Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
    Kimura H; Amino Y; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
    Cancer Commun (Lond); 2019 Nov; 39(1):67. PubMed ID: 31675980
    [No Abstract]   [Full Text] [Related]  

  • 15. Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
    Wang Z; Li X; Zhang L; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Li L; Liu D
    Cancer Med; 2021 May; 10(10):3323-3331. PubMed ID: 33932095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.
    Jiang W; Sha M; Chen C
    Am J Ther; 2023 Nov-Dec 01; 30(6):e570-e572. PubMed ID: 35482932
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
    Niogret J; Coudert B; Boidot R
    J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.
    Wei Q; Zhang J; Chen D; Li S; Liu Y
    Lung Cancer; 2020 Oct; 148():175-176. PubMed ID: 32883519
    [No Abstract]   [Full Text] [Related]  

  • 19. A Case of Adenocarcinoma of the Lung With EGFR T790 Mutation Presenting With Chylous Ascites.
    Nakashima K; Hara Y; Sato T; Shinkai M; Kaneko T
    J Thorac Oncol; 2018 Aug; 13(8):1227-1228. PubMed ID: 29631036
    [No Abstract]   [Full Text] [Related]  

  • 20. Temporal Heterogeneity of Resistance Mechanisms to EGFR-TKI Identified in a Patient With Lung Adenocarcinoma and Sarcomatoid Transformation.
    Zheng J; Zhu J; Zhang K; Yuan M; Chen M; Chen R; Li X
    Clin Lung Cancer; 2020 Jul; 21(4):e255-e257. PubMed ID: 32122806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.